


1646



#11

## RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/813,345A  
Source: 1609  
Date Processed by STIC: 9/3/2002

**RECEIVED**  
SEP 06 2002  
TECH CENTER 1600/2900

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: [patin3help@uspto.gov](mailto:patin3help@uspto.gov) or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:  
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202  
Or  
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

# Raw Sequence Listing Error Summary

## ERROR DETECTED

## SUGGESTED CORRECTION

SERIAL NUMBER: 09/8/3,345A

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1      Wrapped Nucleics  
    Wrapped Aminos      The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
- 2      Invalid Line Length      The rules require that a line not exceed 72 characters in length. This includes white spaces.
- 3      Misaligned Amino  
    Numbering      The numbering under each 5<sup>th</sup> amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
- 4      Non-ASCII      The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5      Variable Length      Sequence(s)          contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6      PatentIn 2.0  
    "bug"      A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s)         . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 7      Skipped Sequences  
    (OLD RULES)      Sequence(s)          missing. If intentional, please insert the following lines for each skipped sequence:  
    (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  
    (i)      SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)  
    (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  
    This sequence is intentionally skipped  
  
    Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
- 8      Skipped Sequences  
    (NEW RULES)      Sequence(s)          missing. If intentional, please insert the following lines for each skipped sequence.  
    <210> sequence id number  
    <400> sequence id number  
    000
- 9      Use of n's or Xaa's  
    (NEW RULES)      Use of n's and/or Xaa's have been detected in the Sequence Listing.  
    Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.  
    In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 10      Invalid <213>  
    Response      Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
- 11      Use of <220>      Sequence(s)          missing the <220> "Feature" and associated numeric identifiers and responses.  
    Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.  
    (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
- 12      PatentIn 2.0  
    "bug"      Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
- 13      Misuse of n      n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.



1600

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/813,345A

DATE: 09/03/2002  
TIME: 15:26:59

Input Set : A:\PTO.VSK.txt  
Output Set: N:\CRF4\09032002\I813345A.raw

Does Not Comply  
Corrected Diskette Needed

pp 1-5

3 <110> APPLICANT: CREIGHTON UNIVERSITY  
4 SMITH, Derek  
5 SAHA, Shankar  
6 ABEL, Peter  
8 <120> TITLE OF INVENTION: PEPTIDE ANTAGONISTS OF CGRP-RECEPTOR SUPERFAMILY AND METHODS  
OF USE  
10 <130> FILE REFERENCE: 180.00020102  
12 <140> CURRENT APPLICATION NUMBER: 09/813,345A  
13 <141> CURRENT FILING DATE: 2001-03-20  
15 <150> PRIOR APPLICATION NUMBER: 09/070,504  
16 <151> PRIOR FILING DATE: 1998-04-30  
18 <160> NUMBER OF SEQ ID NOS: 23  
20 <170> SOFTWARE: PatentIn version 3.0  
22 <210> SEQ ID NO: 1  
23 <211> LENGTH: 30  
24 <212> TYPE: PRT  
C--> 25 <213> ORGANISM: Artificial  
27 <220> FEATURE:  
28 <223> OTHER INFORMATION: peptide (global error) insufficient explanation - give source  
30 <400> SEQUENCE: 1  
32 Val Thr His Arg Leu Ala Gly Leu Leu Ser Arg Ser Gly Gly Met Val  
33 1 5 10 15  
35 Lys Ser Asn Phe Val Pro Thr Asn Val Gly Ser Lys Ala Phe  
36 20 25 30  
38 <210> SEQ ID NO: 2  
39 <211> LENGTH: 30  
40 <212> TYPE: PRT  
C--> 41 <213> ORGANISM: Artificial  
43 <220> FEATURE:  
44 <223> OTHER INFORMATION: peptide (see item 11 on Error Summary Sheet)  
46 <400> SEQUENCE: 2  
48 Val Thr His Arg Leu Ala Gly Leu Leu Ser Arg Ser Gly Gly Val Val  
49 1 5 10 15  
51 Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser Lys Ala Phe  
52 20 25 30  
54 <210> SEQ ID NO: 3  
55 <211> LENGTH: 37  
56 <212> TYPE: PRT  
C--> 57 <213> ORGANISM: Artificial  
59 <220> FEATURE:  
60 <223> OTHER INFORMATION: peptide  
62 <400> SEQUENCE: 3  
64 Ala Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
65 1 5 10 15

## RAW SEQUENCE LISTING

DATE: 09/03/2002

PATENT APPLICATION: US/09/813,345A

TIME: 15:26:59

Input Set : A:\PTO.VSK.txt

Output Set: N:\CRF4\09032002\I813345A.raw

67 Ser Arg Ser Gly Gly Met Val Lys Ser Asn Phe Val Pro Thr Asn Val  
68                   20                   25                   30  
70 Gly Ser Lys Ala Phe  
71                   35  
73 <210> SEQ ID NO: 4  
74 <211> LENGTH: 37  
75 <212> TYPE: PRT  
C--> 76 <213> ORGANISM: Artificial  
78 <220> FEATURE:  
79 <223> OTHER INFORMATION: peptide  
81 <400> SEQUENCE: 4  
83 Ala Cys Asp Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
84 1                   5                   10                   15  
86 Ser Arg Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val  
87                   20                   25                   30  
89 Gly Ser Lys Ala Phe  
90                   35  
92 <210> SEQ ID NO: 5  
93 <211> LENGTH: 37  
94 <212> TYPE: PRT  
C--> 95 <213> ORGANISM: Artificial  
97 <220> FEATURE:  
98 <223> OTHER INFORMATION: peptide  
100 <400> SEQUENCE: 5  
102 Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
103 1                   5                   10                   15  
105 Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val  
106                   20                   25                   30  
108 Gly Ser Lys Ala Phe  
109                   35  
111 <210> SEQ ID NO: 6  
112 <211> LENGTH: 37  
113 <212> TYPE: PRT  
C--> 114 <213> ORGANISM: Artificial  
116 <220> FEATURE:  
117 <223> OTHER INFORMATION: peptide  
119 <400> SEQUENCE: 6  
121 Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
122 1                   5                   10                   15  
124 Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val  
125                   20                   25                   30  
127 Gly Ser Glu Ala Phe  
128                   35  
130 <210> SEQ ID NO: 7  
131 <211> LENGTH: 37  
132 <212> TYPE: PRT  
C--> 133 <213> ORGANISM: Artificial  
135 <220> FEATURE:  
136 <223> OTHER INFORMATION: peptide

## RAW SEQUENCE LISTING

DATE: 09/03/2002

PATENT APPLICATION: US/09/813,345A

TIME: 15:27:00

Input Set : A:\PTO.VSK.txt

Output Set: N:\CRF4\09032002\I813345A.raw

138 <400> SEQUENCE: 7  
140 Ala Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Asp Phe Leu  
141 1 5 10 15  
143 Ser Arg Ser Gly Gly Val Gly Lys Asn Asn Phe Val Pro Thr Asn Val  
144 20 25 30  
146 Gly Ser Lys Ala Phe  
147 35  
149 <210> SEQ ID NO: 8  
150 <211> LENGTH: 37  
151 <212> TYPE: PRT  
C--> 152 <213> ORGANISM: Artificial  
154 <220> FEATURE:  
155 <223> OTHER INFORMATION: peptide  
157 <400> SEQUENCE: 8  
159 Gly Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
160 1 5 10 15  
162 Ser Arg Ser Gly Gly Met Val Lys Ser Asn Phe Val Pro Thr Asn Val  
163 20 25 30  
165 Gly Ser Glu Ala Phe  
166 35  
168 <210> SEQ ID NO: 9  
169 <211> LENGTH: 37  
170 <212> TYPE: PRT  
C--> 171 <213> ORGANISM: Artificial  
173 <220> FEATURE:  
174 <223> OTHER INFORMATION: peptide  
176 <400> SEQUENCE: 9  
178 Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
179 1 5 10 15  
181 Ser Arg Ser Gly Gly Met Val Lys Ser Asn Phe Val Pro Thr Asp Val  
182 20 25 30  
184 Gly Ser Glu Ala Phe  
185 35  
187 <210> SEQ ID NO: 10  
188 <211> LENGTH: 37  
189 <212> TYPE: PRT  
C--> 190 <213> ORGANISM: Artificial  
192 <220> FEATURE:  
193 <223> OTHER INFORMATION: peptide  
195 <400> SEQUENCE: 10  
197 Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
198 1 5 10 15  
200 Ser Arg Ser Gly Gly Val Val Lys Ser Asn Phe Val Pro Thr Asn Val  
201 20 25 30  
203 Gly Ser Gln Ala Phe  
204 35  
206 <210> SEQ ID NO: 11  
207 <211> LENGTH: 37  
208 <212> TYPE: PRT

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/813,345A

DATE: 09/03/2002  
TIME: 15:27:00

Input Set : A:\PTO.VSK.txt  
Output Set: N:\CRF4\09032002\I813345A.raw

C--> 209. <213> ORGANISM: Artificial

211 <220> FEATURE:

212 <223> OTHER INFORMATION: peptide

214 <400> SEQUENCE: 11

216 Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu

217 1 5 10 15

219 Ser Arg Ser Gly Gly Val Val Lys Ser Asn Phe Val Pro Thr Asn Val

220 20 25 30

222 Gly Ser Glu Ala Phe

223 35

225 <210> SEQ ID NO: 12

226 <211> LENGTH: 37

227 <212> TYPE: PRT

C--> 228 <213> ORGANISM: Artificial

230 <220> FEATURE:

231 <223> OTHER INFORMATION: peptide

233 <400> SEQUENCE: 12

235 Ala Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Asp Phe Leu

236 1 5 10 15

238 Asn Arg Ser Gly Gly Met Gly Asn Ser Asn Phe Val Pro Thr Asn Val

239 20 25 30

241 Gly Ala Lys Ala Phe

242 35

244 <210> SEQ ID NO: 13

245 <211> LENGTH: 37

246 <212> TYPE: PRT

C--> 247 <213> ORGANISM: Artificial

249 <220> FEATURE:

250 <223> OTHER INFORMATION: peptide

252 <400> SEQUENCE: 13

254 Ala Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Asp Phe Leu

255 1 5 10 15

257 Ser Arg Ser Gly Gly Met Ala Lys Asn Asn Phe Val Pro Thr Asn Val

258 20 25 30

260 Gly Ser Lys Ala Phe

261 35

263 <210> SEQ ID NO: 14

264 <211> LENGTH: 52

265 <212> TYPE: PRT

C--> 266 <213> ORGANISM: Artificial

268 <220> FEATURE:

269 <223> OTHER INFORMATION: peptide

271 <400> SEQUENCE: 14

273 Tyr Arg Gln Ser Met Asn Asn Phe Gln Gly Leu Arg Ser Phe Gly Cys

274 1 5 10 15

276 Arg Phe Gly Thr Cys Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln

277 20 25 30

279 Phe Thr Asp Lys Asp Lys Asp Asn Val Ala Pro Arg Ser Lys Ile Ser

280 35 40 45

## RAW SEQUENCE LISTING

DATE: 09/03/2002

PATENT APPLICATION: US/09/813,345A

TIME: 15:27:00

Input Set : A:\PTO.VSK.txt

Output Set: N:\CRF4\09032002\I813345A.raw

282 Pro Gln Gly Tyr  
283 50  
285 <210> SEQ ID NO: 15  
286 <211> LENGTH: 50  
287 <212> TYPE: PRT  
C--> 288 <213> ORGANISM: Artificial  
290 <220> FEATURE:  
291 <223> OTHER INFORMATION: peptide  
293 <400> SEQUENCE: 15  
295 Tyr Arg Gln Ser Met Asn Gln Gly Ser Arg Ser Thr Gly Cys Arg Phe  
296 1 5 10 15  
298 Gly Thr Cys Thr Met Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr  
299 20 25 30  
301 Asp Lys Asp Lys Asp Gly Met Ala Pro Arg Asn Lys Ile Ser Pro Gln  
302 35 40 45  
304 Gly Tyr  
305 50  
307 <210> SEQ ID NO: 16  
308 <211> LENGTH: 37  
309 <212> TYPE: PRT  
C--> 310 <213> ORGANISM: Artificial  
312 <220> FEATURE:  
313 <223> OTHER INFORMATION: peptide  
315 <400> SEQUENCE: 16  
317 Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu  
318 1 5 10 15  
320 Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val  
321 20 25 30  
323 Gly Ser Asn Thr Tyr  
324 35  
326 <210> SEQ ID NO: 17  
327 <211> LENGTH: 37  
328 <212> TYPE: PRT  
C--> 329 <213> ORGANISM: Artificial  
331 <220> FEATURE:  
332 <223> OTHER INFORMATION: peptide  
334 <400> SEQUENCE: 17  
336 Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu  
337 1 5 10 15  
339 Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val  
340 20 25 30  
342 Gly Ser Asn Thr Tyr  
343 35  
345 <210> SEQ ID NO: 18  
346 <211> LENGTH: 30  
347 <212> TYPE: PRT  
C--> 348 <213> ORGANISM: Artificial  
350 <220> FEATURE:  
351 <223> OTHER INFORMATION: peptide

*please correct any  
subrequest sequences  
showing the above error*